The U.S. Food and Drug Administration (FDA) granted initial approval to Redemplo (plozasiran) on November 18, 2025. This significant regulatory milestone designates plozasiran as a Type 1 - New Molecular Entity, indicating its active ingredient has not been previously approved. The approval marks a new therapeutic option brought forward by sponsor ARROWHEAD.
Background
Plozasiran, marketed under the brand name Redemplo, has received an initial approval from the FDA, classifying it as a Type 1 - New Molecular Entity. This classification is reserved for drugs containing an active ingredient that has never before been marketed in the United States. Such approvals often represent advancements in medical science, potentially offering novel mechanisms of action or targeting previously untreatable conditions. The development and approval of Redemplo were sponsored by ARROWHEAD.
What this means
The initial approval of Redemplo (plozasiran) as a New Molecular Entity is a notable event for the medical community and patients. As a Type 1 classification, it signifies the introduction of a new active ingredient, which may offer a distinct therapeutic approach or address an unmet medical need. This approval expands the available pharmacopeia, providing clinicians with a new tool in their treatment arsenal.
Source
The information regarding the initial approval of Redemplo (plozasiran) was obtained from the U.S. Food and Drug Administration (FDA). This approval, identified by NDA 219947, was officially recorded on November 18, 2025, and is available on accessdata.fda.gov.